MedDeviceGuide — IVD & Medical Device Knowledge Base

How to establish and justify preventive maintenance and calibration intervals for medical devices — manufacturer recommendations vs. risk-based alternative approaches, statistical methods for interval optimization, reliability-centered maintenance for healthcare, Joint Commission EC.02.04.01 and AEM program requirements, AAMI EQ56 guidance, ISO 13485 Clause 7.5.1 and Clause 7.5.6, FDA 21 CFR Part 820 calibration requirements, and documentation for audit readiness.

How to assign process validation ownership between OEM and CMO/CDMO for medical device manufacturing — protocol authorship, IQ/OQ/PQ execution responsibility, approval authority, and regulatory accountability under ISO 13485, FDA QMSR, and GHTF guidance.

Roche entered a definitive agreement to acquire PathAI on May 7, 2026, for $750M upfront plus up to $300M in milestone payments, adding the AISight digital pathology platform and AI-based biomarker algorithms to its diagnostics division. Covers PathAI's technology for cancer screening and companion diagnostic development, the $1.1B+ AI pathology market, regulatory considerations for AI/ML-based SaMD, and implications for precision oncology and IVD regulatory strategy.

How to qualify sample pads, conjugate pads, and absorbent pads for lateral flow assay IVD products — material selection, pretreatment chemistry, lot-to-lot consistency testing, incoming material specifications, and regulatory requirements under FDA QMSR and ISO 13485.

How to qualify and control sensor and transducer suppliers for medical devices — covering pressure sensors, SpO2 photodetectors, thermistors, force sensors, and airflow transducers, with guidance on ISO 13485 critical supplier classification, accuracy and calibration verification, incoming inspection protocols, ISO 80601-2-61 and IEC 60601 compliance, lot-to-lot performance bridging, quality agreement requirements, and ongoing supplier monitoring for Class II and Class III devices.

How to manage spare parts obsolescence for medical devices throughout the product lifecycle — proactive monitoring, last-time buy strategy, alternate part identification and qualification, verification and validation requirements, engineering change control, 510(k) assessment triggers, EU MDR obligations for discontinued devices, and building an obsolescence management program under ISO 13485 and FDA QMSR.

How to manage sterilization supplier strategy and capacity risk for medical devices — EtO facility closure impact, cobalt-60 supply chain concentration, dual-source qualification, alternative modality readiness (X-ray, e-beam, VH2O2), quality agreement requirements, and supply chain resilience planning under FDA QMSR and ISO 13485.

How to qualify a medical tubing and extrusion supplier — covering supplier selection criteria, quality system audit, IQ/OQ/PQ process validation, dimensional specification control, material traceability, cleanroom requirements, quality agreement structure, and ongoing monitoring for catheter, IV set, and fluid delivery tubing under FDA QMSR, ISO 13485, and EU MDR.

CareDx agreed to acquire Naveris for up to $260M on April 28, 2026, marking its strategic expansion from transplant diagnostics into HPV-driven cancer surveillance. Covers NavDx liquid biopsy technology, TTMV DNA biomarker science, deal structure ($160M upfront + $100M milestones), CareDx's divestiture of Lab Products, and the $4.5B molecular residual disease monitoring market.

Johnson & Johnson entered a definitive agreement to acquire Atraverse Medical on April 24, 2026, adding the FDA-cleared HOTWIRE Transseptal Access System to its cardiac ablation portfolio. Covers RF-guidewire technology for left-heart access, the Atraverse founding team behind Farapulse (Boston Scientific), J&J's electrophysiology strategy including Shockwave and Varipulse, and the competitive landscape in the $10B+ cardiac rhythm management market.

Stryker completed its acquisition of Amplitude Vascular Systems on May 7, 2026, adding next-generation intravascular lithotripsy (IVL) technology to its peripheral vascular portfolio. Covers the CO2-generated pressure wave platform, why IVL matters for calcified PAD treatment, competitive dynamics with J&J/Shockwave, regulatory pathway, and implications for the $4B+ peripheral vascular device market.

In-depth analysis of Bayer's acquisition of Perfuse Therapeutics for up to $2.45 billion, marking its return to M&A after a 5-year drought. Covers the PER-001 intravitreal implant for glaucoma and diabetic retinopathy, deal structure, endothelin receptor antagonism mechanism, the growing drug-device combination product market, and what it means for ophthalmic medtech manufacturers and investors.

GE HealthCare announced a sweeping restructuring of its business segments and executive leadership team alongside Q1 2026 earnings that missed expectations. Facing $250M in inflationary cost increases driven by memory chips, oil, and freight, the company is raising prices and cutting its profit outlook. Covers the new Advanced Imaging Solutions segment, leadership changes, the inflation impact on medtech supply chains, and what device manufacturers should expect.

Sun Pharmaceutical Industries agreed to acquire Organon & Co. for $11.75 billion in the largest pharmaceutical deal of 2026 and India's largest overseas pharma acquisition. Covers deal structure, Organon's portfolio of women's health products (Nexplanon, NuvaRing) and biosimilars (Hadlima, Renflexis), the drug-device combination products involved, regulatory considerations for combination products, and what the deal means for the women's health and biosimilar device landscape.

In-depth analysis of Danaher's $9.9 billion acquisition of Masimo, the largest medtech deal of 2026. Covers deal structure, strategic rationale, regulatory and antitrust considerations, competitive landscape impact on patient monitoring, and what it means for device manufacturers, hospitals, and investors.

Comprehensive guide to the EU's new Breakthrough Device (BtX) framework under MDCG 2025-9 and the EMA pilot program launching Q2 2026. Covers eligibility criteria, application process, benefits for manufacturers, comparison with the FDA Breakthrough Device Program, and what this means for IVD companies.

Detailed analysis of MedTech Europe's May 2026 position paper on the proposed MDR/IVDR revision. Covers breakthrough/orphan pathways, cybersecurity, AI integration, IVDR-specific concerns, and what manufacturers need to know about the coming legislative process.

On May 7, 2026, the EU Council and Parliament reached a provisional deal to simplify AI Act rules. This guide breaks down what changed, what the product safety exemption means for medical devices, the new compliance timelines for AI-enabled SaMD and IVDs, and what manufacturers must do now.

Breaking down the FDA's May 2026 one-day inspection pilot that uses AI (Elsa) to target low-risk facilities. Covers how facilities are selected, what to expect during a screening inspection, how it differs from standard inspections, and what medical device manufacturers must do to stay ready.

The FDA's April 2026 real-time clinical trials initiative uses AI and cloud computing to monitor trial data as it is generated. This guide explains how the program works, the Paradigm Health platform, implications for medical device clinical investigations, and what sponsors must prepare to participate.